Literature DB >> 28646524

Risk factors for severe respiratory depression from prescription opioid overdose.

Lindsay M Fox1, Robert S Hoffman1, David Vlahov2, Alex F Manini3.   

Abstract

BACKGROUND AND AIMS: Prescription opioid overdose is a leading cause of injury-related morbidity and mortality in the United States. We aimed to identify characteristics associated with clinical severity in emergency department patients with prescription opioid overdose.
DESIGN: This was a secondary data analysis of adult prescription opioid overdoses from a large prospective cohort of acute overdoses. We examined elements of a typical emergency department evaluation using a multivariable model to determine which characteristics were associated with clinical severity, specifically severe respiratory depression (SRD).
SETTING: This study was conducted at two urban academic emergency departments in New York City, USA. PARTICIPANTS: Adult patients who presented with acute prescription opioid overdose between 2009 and 2013 were included in the current study. We analyzed 307 patients (mean age = 44.7, 42% female, 2.0% mortality). MEASUREMENTS: Patient demographics, reported substances ingested, suspected intent for ingesting the substance, vital signs, laboratory data, treatments including antidotes and intubation and outcome of death were recorded by trained research assistants. Intent was categorized into four mutually exclusive categories: suicide, misuse, therapeutic error and undetermined. The primary outcome was SRD, defined as administration of either (a) naloxone or (b) endotracheal intubation (ETI).
FINDINGS: A total of 109 patients suffered SRD with 90 patients receiving naloxone alone, nine ETI alone and 10 both naloxone and ETI. The most common opioids were oxycodone (n = 124) and methadone (n = 116). Mean age was higher in patients with SRD (51.1 versus 41.1, P < 0.001). Opioid misuse was associated with SRD in the multivariable analysis [odds ratio (OR) = 2.07, 95% confidence interval (CI) = 1.21-3.55]. The unadjusted relative risk of SRD was high for fentanyl (83.3% SRD) and lowest for codeine (3.6% SRD).
CONCLUSION: In emergency department patients in the United States with prescription opioid overdose, worse clinical severity was associated with opioid misuse, increased with age and was widely variable, depending on the specific opioid medication involved.
© 2017 Society for the Study of Addiction.

Entities:  

Keywords:  Drug abuse; drug overdose; emergency medicine; hypoventilation; naloxone; opioid-related disorders

Mesh:

Substances:

Year:  2017        PMID: 28646524      PMCID: PMC5725269          DOI: 10.1111/add.13925

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  17 in total

1.  Clinical risk factors for in-hospital adverse cardiovascular events after acute drug overdose.

Authors:  Alex F Manini; Robert S Hoffman; Barry Stimmel; David Vlahov
Journal:  Acad Emerg Med       Date:  2015-04-22       Impact factor: 3.451

Review 2.  Reducing opioid analgesic deaths in America: what health providers can do.

Authors:  Taghogho Agarin; Andrea M Trescot; Aniefiok Agarin; Doreena Lesanics; Claricio Decastro
Journal:  Pain Physician       Date:  2015 May-Jun       Impact factor: 4.965

3.  Prescription opioid duration of action and the risk of unintentional overdose among patients receiving opioid therapy.

Authors:  Matthew Miller; Catherine W Barber; Sarah Leatherman; Jennifer Fonda; John A Hermos; Kelly Cho; David R Gagnon
Journal:  JAMA Intern Med       Date:  2015-04       Impact factor: 21.873

4.  Validation of Criteria to Guide Prehospital Naloxone Administration for Drug-Related Altered Mental Status.

Authors:  Matt S Friedman; Alex F Manini
Journal:  J Med Toxicol       Date:  2016-04-15

5.  Opioid prescriptions for chronic pain and overdose: a cohort study.

Authors:  Kate M Dunn; Kathleen W Saunders; Carolyn M Rutter; Caleb J Banta-Green; Joseph O Merrill; Mark D Sullivan; Constance M Weisner; Michael J Silverberg; Cynthia I Campbell; Bruce M Psaty; Michael Von Korff
Journal:  Ann Intern Med       Date:  2010-01-19       Impact factor: 25.391

6.  Could chest wall rigidity be a factor in rapid death from illicit fentanyl abuse?

Authors:  Glenn Burns; Rebecca T DeRienz; Daniel D Baker; Marcel Casavant; Henry A Spiller
Journal:  Clin Toxicol (Phila)       Date:  2016-03-21       Impact factor: 4.467

Review 7.  Emergency medical services naloxone access: a national systematic legal review.

Authors:  Corey S Davis; Jessica K Southwell; Virginia Radford Niehaus; Alexander Y Walley; Michael W Dailey
Journal:  Acad Emerg Med       Date:  2014-10       Impact factor: 3.451

8.  Mortality after prison release: opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009.

Authors:  Ingrid A Binswanger; Patrick J Blatchford; Shane R Mueller; Marc F Stern
Journal:  Ann Intern Med       Date:  2013-11-05       Impact factor: 25.391

9.  The relative risk of fatal poisoning by methadone or buprenorphine within the wider population of England and Wales.

Authors:  Dave Marteau; Rebecca McDonald; Kamlesh Patel
Journal:  BMJ Open       Date:  2015-05-29       Impact factor: 2.692

10.  Validation of a Screening Risk Index for Serious Prescription Opioid-Induced Respiratory Depression or Overdose in a US Commercial Health Plan Claims Database.

Authors:  Barbara K Zedler; William B Saunders; Andrew R Joyce; Catherine C Vick; E Lenn Murrelle
Journal:  Pain Med       Date:  2018-01-01       Impact factor: 3.750

View more
  20 in total

1.  Emergency Department Initiation of Buprenorphine for Opioid Use Disorder: Current Status, and Future Potential.

Authors:  Lindsay Fox; Lewis S Nelson
Journal:  CNS Drugs       Date:  2019-12       Impact factor: 5.749

2.  Emergency Department Visits for Opioid Overdoses Among Patients With Cancer.

Authors:  Vikram Jairam; Daniel X Yang; James B Yu; Henry S Park
Journal:  J Natl Cancer Inst       Date:  2020-09-01       Impact factor: 13.506

3.  Fentanyl and fentanyl-analog involvement in drug-related deaths.

Authors:  Zheng Dai; Marie A Abate; Gordon S Smith; James C Kraner; Allen R Mock
Journal:  Drug Alcohol Depend       Date:  2019-01-09       Impact factor: 4.492

4.  The epidemiology of prescription fentanyl misuse in the United States.

Authors:  Ty S Schepis; Vita V McCabe; Carol J Boyd; Sean Esteban McCabe
Journal:  Addict Behav       Date:  2019-04-22       Impact factor: 3.913

5.  Prescription drug and alcohol simultaneous co-ingestion in U.S. young adults: Prevalence and correlates.

Authors:  Ty S Schepis; Sean Esteban McCabe; Jason A Ford
Journal:  Exp Clin Psychopharmacol       Date:  2021-08-19       Impact factor: 3.157

6.  Monoclonal Antibodies Counteract Opioid-Induced Behavioral and Toxic Effects in Mice and Rats.

Authors:  Carly Baehr; April Huseby Kelcher; Aaron Khaimraj; Dana E Reed; Sujata G Pandit; David AuCoin; Saadyah Averick; Marco Pravetoni
Journal:  J Pharmacol Exp Ther       Date:  2020-09-26       Impact factor: 4.030

Review 7.  γ-Hydroxybutyric Acid: Pharmacokinetics, Pharmacodynamics, and Toxicology.

Authors:  Melanie A Felmlee; Bridget L Morse; Marilyn E Morris
Journal:  AAPS J       Date:  2021-01-08       Impact factor: 4.009

8.  Co-ingestion of prescription drugs and alcohol in US adults aged 50 years or older.

Authors:  Ty S Schepis; Jason A Ford; Sean Esteban McCabe
Journal:  Hum Psychopharmacol       Date:  2021-07-08       Impact factor: 2.130

9.  Prescription opioid policies and associations with opioid overdose and related adverse effects.

Authors:  Valerie S Harder; Susan E Varni; Kimberly A Murray; Timothy B Plante; Andrea C Villanti; Daniel L Wolfson; Sanchit Maruti; Kathleen M Fairfield
Journal:  Int J Drug Policy       Date:  2021-06-06

10.  Time-Dependent Changes in the Serum Levels of Neurobiochemical Factors After Acute Methadone Overdose in Adolescent Male Rat.

Authors:  Leila Ahmad-Molaei; Mahsa Pourhamzeh; Reza Ahadi; Fariba Khodagholi; Hossein Hassanian-Moghaddam; Abbas Haghparast
Journal:  Cell Mol Neurobiol       Date:  2020-07-25       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.